Liraglutide vs TRT for Weight Loss in Hypogonadal Men 16-week Trial Results
Estimated reading time: 9 minutes
Key takeaways
- Liraglutide produced substantially greater 16-week weight loss than TRT (−7.9 kg vs −0.9 kg) with larger reductions in BMI and waist.
- Both treatments improved total testosterone and hypogonadal symptoms; the testosterone rise was numerically larger with TRT, but between-group differences were not statistically significant.
- Liraglutide increased LH/FSH, while TRT suppressed them—key for men concerned about fertility and HPT axis recovery.
- TRT improved insulin resistance (HOMA-IR); liraglutide reduced HbA1c more and resolved metabolic syndrome in some participants.
- Small, single-center, open-label, 16-week study—long-term durability, safety, and fertility outcomes remain uncertain.
Table of contents
Why this comparison matters
Obesity-related, or “functional,” hypogonadism is common in men with higher BMI and metabolic risk. When lifestyle changes aren’t enough, men and their clinicians often consider testosterone replacement therapy (TRT). Increasingly, GLP‑1 receptor agonists like liraglutide (at the 3 mg dose used for chronic weight management) are also part of that conversation. A head-to-head clinical trial offers useful signals on how these options compare for weight loss, metabolic health, testosterone, and symptoms over 16 weeks.
GLP‑1 drugs target weight and glycemia—factors tightly linked to testosterone regulation—while TRT directly raises serum testosterone but can suppress the HPT axis and typically does not cause major weight loss. For men prioritizing weight, metabolic risk, symptoms, or future fertility, understanding the trade‑offs is crucial.
Who was studied
- Adults: 30 men, average age ~46.5 years, with obesity (mean BMI ~41 kg/m²).
- Diagnosis: Functional hypogonadism with total testosterone <11 nmol/L and symptomatic per validated questionnaires.
- Prior care: Insufficient response to lifestyle intervention before enrollment.
- Randomization: Liraglutide 3 mg SC daily vs transdermal 1% testosterone gel 50 mg daily.
- Duration: 16 weeks with assessments every 4 weeks.
This focused population—obese men with presumed metabolic drivers of low testosterone who struggled with lifestyle change—limits generalizability to other hypogonadism types (e.g., primary testicular failure) or normal‑weight men.
The trial at a glance
Design: Prospective, randomized, open‑label, single‑center study. Randomization supports internal validity, but the open‑label design can influence subjective outcomes. The small sample (n=30) and short duration (16 weeks) constrain precision and long‑term inference.
Primary and monitored outcomes included:
- Body weight, BMI, and waist circumference
- Hypogonadal symptom burden (e.g., AMS scores) and sexual function
- Total testosterone, LH, and FSH
- Insulin resistance (HOMA‑IR) and glycemic measures (e.g., HbA1c)
- Presence of metabolic syndrome
Weight, waist, and metabolic health: clear advantage for liraglutide
- Weight change at 16 weeks:
- Liraglutide: −7.9 ± 3.8 kg (−6.0 ± 3.2%)
- TRT: −0.9 ± 4.5 kg (−0.8 ± 3.3%)
- Central adiposity: Liraglutide significantly reduced waist circumference; TRT changes were modest and not statistically significant.
- Metabolic syndrome: Resolved in 2/15 on liraglutide vs 0/15 on TRT over 16 weeks.
Insulin/glycemic markers:
- HOMA‑IR improved (decreased) in the TRT arm.
- HbA1c improved more with liraglutide.
These results align with GLP‑1 mechanisms: clinically meaningful weight loss and better glycemic control with reductions in central adiposity—a key driver of functional hypogonadism. While TRT improved insulin sensitivity, it did not match liraglutide for weight or waist change over 16 weeks.
Symptoms and testosterone: both improved
Both groups reported improvements in sexual function and hypogonadal symptoms, tracked every four weeks using standardized tools.
- Total testosterone change at 16 weeks:
- TRT: +5.9 ± 7.2 nmol/L
- Liraglutide: +2.6 ± 3.5 nmol/L
Between‑group differences in testosterone were not statistically significant in this small study. TRT directly raises serum testosterone; liraglutide’s gains likely reflect weight/fat loss and improved metabolic milieu.
Fertility and the HPT axis: a key divergence
- Liraglutide increased LH and FSH (P<0.001 vs TRT), suggesting normalization of central signaling.
- TRT suppressed LH/FSH, reflecting expected negative feedback on the HPT axis.
Why it matters: Suppressed gonadotropins on TRT can reduce intratesticular testosterone, impair spermatogenesis, and delay fertility recovery after discontinuation. By reducing adiposity and potentially relieving central suppression, a GLP‑1 approach may support endogenous axis recovery rather than suppress it.
Safety and tolerability: what the trial can—and cannot—tell us
This 16‑week, small, open‑label study was not powered for comprehensive safety outcomes. General considerations apply:
- Liraglutide (3 mg daily):
- Common: dose‑dependent GI effects (nausea, vomiting, diarrhea), especially during titration.
- Warnings: pancreatitis risk; certain populations were excluded in the trial.
- Metabolic: favorable effects on weight/glycemia and cardiovascular risk markers observed in broader GLP‑1 literature.
- TRT (1% transdermal gel 50 mg daily):
- Risks: erythrocytosis, acne/oily skin, effects on PSA/prostate, edema, and potential exacerbation of untreated sleep apnea.
- HPT suppression may impair fertility during treatment.
Because adverse‑event capture is limited here by size and duration, decisions should lean on broader safety data and individual risk profiles.
Practical implications for men considering liraglutide vs TRT
Who might favor liraglutide (GLP‑1 approach)?
- Men prioritizing weight reduction, waist loss, and metabolic risk improvement.
- Men wishing to avoid HPT axis suppression and maintain or recover fertility.
- Those with prediabetes or glycemic concerns who may benefit from HbA1c reduction.
Who might favor TRT?
- Men seeking a more direct and often faster rise in serum testosterone to relieve hypogonadal symptoms.
- Men without near‑term fertility goals who accept HPT suppression as part of therapy.
- Men who have tried or are not candidates for GLP‑1 therapy, or who experience intolerable GLP‑1 side effects.
Monitoring and follow‑up:
- Symptom tracking every 4–12 weeks (e.g., AMS or similar).
- Labs: morning total testosterone, SHBG if indicated, LH/FSH, hematocrit/hemoglobin, PSA as age‑appropriate, HbA1c/fasting glucose/HOMA‑IR, lipids.
- Anthropometrics: weight and waist circumference.
- Document and revisit fertility goals regularly.
Combination or sequencing? Not addressed by this trial. A practical approach is starting with a GLP‑1 to improve weight/metabolic drivers, then reassessing testosterone and symptoms before initiating or resuming TRT. Evidence for combination therapy is limited and should be individualized.
What we still don’t know
- Durability beyond 16 weeks for weight loss, symptom relief, and hormonal normalization.
- Cardiovascular and renal outcomes in this specific population.
- Fertility outcomes and long‑term HPT recovery with GLP‑1 vs TRT.
- Comparative data with newer GLP‑1 RAs (e.g., semaglutide; SEMAT trial ongoing).
- Real‑world adherence, access, cost, and tolerability.
- Formulation effects: this study used transdermal gel; results may differ with injections or other regimens.
How Taurus Meds can support
Men rarely fit neatly into a single treatment path. At Taurus Meds, we help patients and clinicians explore evidence‑based options—whether prioritizing weight loss, symptom relief, fertility, or all three. We support careful baseline evaluation, shared decision‑making, and structured follow‑up so therapy aligns with each person’s goals and risk profile.
Bottom line
In obese men with functional hypogonadism who did not respond to lifestyle interventions, a 16‑week randomized trial suggests liraglutide 3 mg daily delivers substantially greater weight and waist reduction than TRT, improves hypogonadal symptoms, raises gonadotropins, and can resolve metabolic syndrome in some cases. Both treatments improved testosterone levels and symptoms, with TRT showing a larger numerical increase in total testosterone but at the expected cost of HPT axis suppression.
For many men whose low testosterone is closely tied to excess weight and metabolic dysfunction, a GLP‑1–based strategy may be a strong first step. For others, particularly those seeking rapid testosterone normalization and who are not prioritizing fertility, TRT remains a reasonable option. Because evidence is short‑term and individual goals differ, the best choice is the one made with a clinician who understands both the endocrine and cardiometabolic sides of men’s health.
Disclaimer
This article is for educational purposes only and is not medical advice. Decisions about diagnosing or treating hypogonadism, initiating TRT, or using GLP‑1 therapies should be made with a qualified healthcare professional who can consider your full medical history and goals.